AWM
RPRX icon

Abound Wealth Management’s Royalty Pharma RPRX Stock Holding History

Abound Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 1352
2026
Q1 		– Hold
0
– – – 1485
2025
Q4 		– Hold
0
– – – 1430
2025
Q3 		– Hold
0
– – – 1356
2023
Q3 		– Sell
-20
Closed -$619 – 1213
2023
Q2 		$619 Buy
+20
New +$677 ﹤0.01% 789

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abound Wealth Management's RPRX Position: Q2 2026 in Review

Abound Wealth Management held its Royalty Pharma (RPRX) position steady in Q2 2026 at 0 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #1352.

Abound Wealth Management first reported a position in RPRX in Q2 2023 and has held it in 1 quarter since. The position peaked at $619 in Q2 2023. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Abound Wealth Management held 0 shares of Royalty Pharma worth $8 as of Q2 2026.
  • Abound Wealth Management left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1352 holding.
  • Abound Wealth Management first reported a position in Royalty Pharma in Q2 2023 and has held it in 1 quarter since.
  • Abound Wealth Management's Royalty Pharma position peaked at $619 in Q2 2023.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.